Amneal Acquires Kashiv BioSciences to Build Biosimilar Empire
Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, forming an end-to-end global biosimilar platform.
Amneal Pharmaceuticals has finalized its acquisition of Kashiv BioSciences, a move the company says positions it as a global leader in the fast-growing biosimilars market. The deal closes a strategic push to consolidate research, manufacturing, and commercial capabilities under a single integrated structure — a rare combination in an industry where those functions are often spread across multiple partners.
Biosimilars — lower-cost alternatives to complex biologic drugs — have become one of the most competitive and high-stakes segments in pharmaceuticals as major biologic patents expire. By absorbing Kashiv, Amneal gains direct control over the full product lifecycle, from early-stage R&D through large-scale manufacturing and eventual commercialization, reducing dependence on third-party contractors and potentially accelerating time-to-market.
Read more Lamborghini Revuelto SV Debuts as Brand's Most Powerful Car Ever →
The integrated platform is expected to strengthen Amneal's pipeline and give the company a structural cost advantage over rivals that must stitch together external partnerships to bring biosimilars to patients. Analysts have long viewed vertical integration as a key differentiator in the biosimilars race, where margins can be thin and regulatory hurdles are substantial.
The acquisition signals Amneal's ambition to compete not just domestically but on a global scale, as demand for affordable biologics rises across international markets. With Kashiv's scientific expertise now embedded within Amneal's broader infrastructure, the combined entity is expected to accelerate biosimilar development timelines and expand its addressable market considerably.
Continue reading at GlobalNewswire.
